RIPK1 inhibitors such as GSK481/547/963, Nec-1, and RIPA-56, and the RIPK3 inhibitor GSK872, are verified to inhibit various inflammation-associated diseases, including COPD and ALI [118,159,160,161]. This evidence concerns the gene RIPK3 and chronic obstructive pulmonary disease.